📊 BOLD Key Takeaways
Is Boundless Bio, Inc. (BOLD) a Good Investment?
Boundless Bio is a pre-revenue pharmaceutical company with severe operational losses (-$63.6M operating income) and negative free cash flow (-$47.2M), indicating the company is consuming cash at an unsustainable rate. With only $17.9M in cash against $46.7M annual operating burn, the company faces a critical liquidity crisis within months without additional financing. The company shows no clear path to profitability or revenue generation based on available financial data.
Boundless Bio remains a pre-revenue biotech with deep operating losses and negative free cash flow, so the core fundamental story is still driven by capital consumption rather than business profitability. The balance sheet is relatively clean, with no long-term debt and strong reported liquidity, but the company’s cash burn and lack of commercial revenue keep execution risk high. Fundamental improvement will depend on materially narrowing losses and sustaining liquidity without heavy shareholder dilution.
Why Buy Boundless Bio, Inc. Stock? BOLD Key Strengths
- Strong balance sheet structure with minimal debt (0.00x debt/to-equity)
- Excellent short-term liquidity with 8.74x current ratio despite operational losses
- Biotech sector allows for transformative potential if pipeline succeeds
- Debt-free balance sheet reduces financial distress risk
- Very strong current and quick ratios indicate ample near-term liquidity
- Positive year-over-year EPS improvement suggests some operating cost discipline
BOLD Stock Risks: Boundless Bio, Inc. Investment Risks
- Severe cash burn rate ($46.7M annual operating outflow) with only $17.9M cash runway (~4.6 months)
- No revenue generation with $63.6M operating losses in pharmaceutical development stage
- Negative ROE (-59.0%) and ROA (-37.1%) demonstrate value destruction and poor asset utilization
- Pre-clinical/early-stage biotech company faces high clinical development risk and regulatory uncertainty
- Likely requires immediate equity dilution or debt financing to avoid insolvency
- No reported revenue means the business model is not yet self-funding
- Large operating and free cash flow losses indicate continued cash burn
- High likelihood of future external financing or dilution if losses persist
Key Metrics to Watch
- Cash runway and quarterly burn rate to assess survival timeline
- Clinical trial progress and pipeline advancement announcements
- Future financing activities and dilution impact on shareholder value
- Quarterly operating cash burn and total liquidity runway
- Any emergence of sustainable revenue or major reduction in operating losses
Boundless Bio, Inc. (BOLD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.74x current ratio provides a solid financial cushion.
BOLD Profit Margin, ROE & Profitability Analysis
BOLD vs Healthcare Sector: How Boundless Bio, Inc. Compares
How Boundless Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Boundless Bio, Inc. Stock Overvalued? BOLD Valuation Analysis 2026
Based on fundamental analysis, Boundless Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Boundless Bio, Inc. Balance Sheet: BOLD Debt, Cash & Liquidity
BOLD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Boundless Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.85 indicates the company is currently unprofitable.
BOLD Revenue Growth, EPS Growth & YoY Performance
Boundless Bio, Inc. Dividends, Buybacks & Capital Allocation
BOLD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Boundless Bio, Inc. (CIK: 0001782303)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BOLD
What is the AI rating for BOLD?
Boundless Bio, Inc. (BOLD) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BOLD's key strengths?
Claude: Strong balance sheet structure with minimal debt (0.00x debt/to-equity). Excellent short-term liquidity with 8.74x current ratio despite operational losses. ChatGPT: Debt-free balance sheet reduces financial distress risk. Very strong current and quick ratios indicate ample near-term liquidity.
What are the risks of investing in BOLD?
Claude: Severe cash burn rate ($46.7M annual operating outflow) with only $17.9M cash runway (~4.6 months). No revenue generation with $63.6M operating losses in pharmaceutical development stage. ChatGPT: No reported revenue means the business model is not yet self-funding. Large operating and free cash flow losses indicate continued cash burn.
What is BOLD's revenue and growth?
Boundless Bio, Inc. reported revenue of N/A.
Does BOLD pay dividends?
Boundless Bio, Inc. does not currently pay dividends.
Where can I find BOLD SEC filings?
Official SEC filings for Boundless Bio, Inc. (CIK: 0001782303) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BOLD's EPS?
Boundless Bio, Inc. has a diluted EPS of $-2.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BOLD a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Boundless Bio, Inc. has a SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BOLD stock overvalued or undervalued?
Valuation metrics for BOLD: ROE of -59.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BOLD stock in 2026?
Our dual AI analysis gives Boundless Bio, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BOLD's free cash flow?
Boundless Bio, Inc.'s operating cash flow is $-46.7M, with capital expenditures of $546.0K.
How does BOLD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -59.0% (avg: 15%), current ratio 8.74 (avg: 2).